WallStSmart

Monster Beverage Corp (MNST)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 583% more annual revenue ($56.67B vs $8.29B). NVS leads profitability with a 24.7% profit margin vs 23.0%. MNST appears more attractively valued with a PEG of 2.13. MNST earns a higher WallStSmart Score of 68/100 (B-).

MNST

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 9.5Value: 8.7Quality: 7.8
Piotroski: 5/9Altman Z: 5.91

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 4.7Quality: 6.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MNSTUndervalued (+11.0%)

Margin of Safety

+11.0%

Fair Value

$90.79

Current Price

$73.21

$17.58 discount

UndervaluedFair: $90.79Overvalued
NVSSignificantly Overvalued (-243.7%)

Margin of Safety

-243.7%

Fair Value

$48.62

Current Price

$150.75

$102.13 premium

UndervaluedFair: $48.62Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MNST6 strengths · Avg: 9.5/10
Operating MarginProfitability
31.3%10/10

Strong operational efficiency at 31.3%

EPS GrowthGrowth
66.6%10/10

Earnings expanding 66.6% YoY

Altman Z-ScoreHealth
5.9110/10

Safe zone — low bankruptcy risk

Market CapQuality
$71.62B9/10

Large-cap with strong market position

Return on EquityProfitability
26.8%9/10

Every $100 of equity generates 27 in profit

Profit MarginProfitability
23.0%9/10

Keeps 23 of every $100 in revenue as profit

NVS5 strengths · Avg: 9.0/10
Market CapQuality
$286.27B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.8%10/10

Every $100 of equity generates 31 in profit

Profit MarginProfitability
24.7%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability
27.8%8/10

Strong operational efficiency at 27.8%

Free Cash FlowQuality
$1.64B8/10

Generating 1.6B in free cash flow

Areas to Watch

MNST3 concerns · Avg: 4.0/10
PEG RatioValuation
2.134/10

Expensive relative to growth rate

P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.7x4/10

Trading at 8.7x book value

NVS4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
2.2%4/10

2.2% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

PEG RatioValuation
2.542/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.6%2/10

Earnings declined 11.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : MNST

The strongest argument for MNST centers on Operating Margin, EPS Growth, Altman Z-Score. Profitability is solid with margins at 23.0% and operating margin at 31.3%. Revenue growth of 17.6% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.

Bear Case : MNST

The primary concerns for MNST are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.

Key Dynamics to Monitor

MNST profiles as a growth stock while NVS is a value play — different risk/reward profiles.

NVS carries more volatility with a beta of 0.50 — expect wider price swings.

MNST is growing revenue faster at 17.6% — sustainability is the question.

NVS generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

MNST scores higher overall (68/100 vs 51/100), backed by strong 23.0% margins and 17.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Monster Beverage Corp

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Monster Beverage Corporation is an American beverage company that manufactures energy drinks including Monster Energy, Relentless and Burn.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?